Abstract

Purpose To investigate the impact of systemic diseases on the occurrence of subretinal fluid (SRF) in diabetic macular edema (DME) and prognostic factors for residual SRF following three consecutive monthly intravitreal ranibizumab. Methods Ninety-seven eyes from 68 patients with DME who completed 3 consecutive monthly injections of ranibizumab were enrolled. Systemic parameters mainly included chronic kidney disease (CKD), hypertension, HbA1c, and insulin dependence. Renal parameters for CKD were serum creatinine, estimated glomerular filtration rate (eGFR), and serum albumin. Ocular factors were baseline central macular thickness (CMT), severity of diabetic retinopathy (DR), and status of panretinal photocoagulation (PRP). Results Chronic kidney disease had significant correlation with baseline SRF (R = 0.397, p < 0.001 after partial correlation with adjustment for age and DR severity). As for CKD, lower serum albumin, but not eGFR or serum creatinine, was associated with baseline presence of SRF (p = 0.026, p = 0.08 and p = 0.53, resp., after adjustment for age and DR severity). Overall, lower eGFR and lower HbA1c values, contrary to popular belief, predicted the presence of residual SRF following intravitreal injections (p = 0.016 and p < 0.001, resp.). Conclusions Tight sugar control and poorer baseline kidney function may slow the resorption of SRF after anti-VEGF injections in patients with DME in the short term.

Highlights

  • Diabetic macular edema has been one of the leading causes of visual impairment worldwide [1]

  • The purpose of the study is to investigate the role of kidney function in the Journal of Ophthalmology subretinal fluid of diabetic macular edema, and correlating factors for residual fluid following three monthly ranibizumab treatments

  • This research adhered to the tenets of the Declaration of Helsinki, and Institutional Review Board (IRB) approval was obtained from the IRB of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Read more

Summary

Introduction

Diabetic macular edema has been one of the leading causes of visual impairment worldwide [1]. Ranibizumab, a humanized monoclonal antibody that targets intraocular VEGF, is quite effective and safe in the resolution of diabetic macular edema reported by several studies [4, 5]. Subretinal fluid was found to be a favorable indicator for both visual and anatomical improvement following ranibizumab treatment [6]. Other studies observed the increased levels of intraocular VEGF which may contribute to the level of fluid as evidenced by optical coherent tomography reflectivity [12]. The purpose of the study is to investigate the role of kidney function in the Journal of Ophthalmology subretinal fluid of diabetic macular edema, and correlating factors for residual fluid following three monthly ranibizumab treatments

Objectives
Methods
Findings
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.